Life expectancy is an estimate of how much longer a person is likely to live, based on their age, health, and diagnosis. For someone with an asbestos-related disease, it reflects both their normal expected lifespan and how the illness is expected to shorten it. This estimate carries both medical and legal weight.
Origin
The concept comes from actuarial science and public-health statistics developed in the 18th and 19th centuries to price life insurance and measure population health. Standard mortality tables express it as an average number of remaining years for a person of a given age.
Significance in Asbestos Context
Life expectancy sits at the crossroads of medicine and law. Medically, it shapes treatment goals and choices between aggressive care and comfort-focused care. Legally, it drives major parts of a damages claim, including lost future earnings, future medical costs, and the value of pain and suffering over the time remaining. Because mesothelioma often carries a short prognosis, this estimate can significantly affect a case, and it's one reason courts allow expedited or preference trial settings for the seriously ill. Both sides may present expert testimony on it, so a well-documented medical prognosis matters.
Example Sentence
Given his mesothelioma diagnosis, the court granted an expedited trial date because his life expectancy was measured in months.
Related Terms
Prognosis, Damages, Expedited Trial, Pain and Suffering, Lost Future Earnings, Wrongful Death Claim
Notes
- Ask your physician to document your prognosis clearly in the medical record, since both treatment planning and any claim depend on it.
- If your prognosis is short, tell your attorney promptly; many courts grant trial preference to seriously ill plaintiffs.
- Keep records of all treatments and their outcomes, which experts use when estimating remaining life expectancy.
In the research library
54 studies in our medical research library mention Life Expectancy in the title or abstract. Among the most cited:
- Life Expectancy in Pleural and Peritoneal MesotheliomaR. Shavelle, K. Vavra-Musser, J. Lee, et al, 2017 · Lung Cancer International · cited 53 times
- Early and late morbidity and mortality and life expectancy following thoracoscopic talc insufflation for control of malignant pleural effusions: a review of 400 casesN. Barbetakis, C. Asteriou, F. Papadopoulou, et al, 2010 · Journal of Cardiothoracic Surgery · cited 32 times
- Life expectancy of patients with malignant pleural effusion treated with video-assisted thoracoscopic talc pleurodesisT. Laisaar, V. Palmiste, T. Vooder, et al, 2006 · Interactive Cardiovascular and Thoracic Surgery · cited 17 times
- Factors affecting the life expectancy in malignant pleural mesothelioma: Our 10 years of studies and experienceF. Cimen, Y. Agackiran, S. Düzgün, et al, 2022 · Medicine · cited 6 times
- Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 studyA. Marabelle, M. Fakih, J. Lopez, et al, 2020 · The Lancet. Oncology · cited 2,186 times
The journals that publish most on it: The Lancet. Oncology (4), Frontiers in Oncology (3), Cancers (3).
Category: Overlapping Terms (Medical + Legal) · All Lexicon terms A–Z
This page is provided for general informational purposes and does not constitute legal advice. Every asbestos case turns on its own facts, exposure history, diagnosis, deadlines, available evidence, and applicable law. Reviewing this page does not create an attorney-client relationship. For advice about your specific situation, call 833-4-ASBESTOS for a free case review.